Cargando…
363. A Phase II Prospective Randomized Study to Assess Imipenem-Relebactam in the Management of Cancer Patients with Febrile Neutropenia
BACKGROUND: The overuse of antibiotics has led to the emergence of antibiotic resistance that poses a significant threat particularly for the immunocompromised cancer patients. Hence, the empiric therapy with standard antibiotic could be suboptimal in these vulnerable patients who often receive anti...
Autores principales: | Chaftari, Anne-Marie, Dagher, Hiba, Hachem, Ray Y, Jiang, Ying, Lamie, Peter, Dib, Rita Wilson, John, Teny, Haddad, Andrea, Philip, Ann, Ali, Shahnoor, Mulanovich, Patricia, Juan, Ying, Chaftari, Patrick, Raad, Issam I |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10676838/ http://dx.doi.org/10.1093/ofid/ofad500.433 |
Ejemplares similares
-
859. The Role of Procalcitonin in Antimicrobial De-escalation and Stewardship Program in Febrile Neutropenic Cancer Patients
por: Dagher, Hiba, et al.
Publicado: (2023) -
The role of procalcitonin in identifying high‐risk cancer patients with febrile neutropenia: A useful alternative to the multinational association for supportive care in cancer score
por: Chaftari, Patrick, et al.
Publicado: (2021) -
1257. A phase II Prospective Randomized Study to Assess Ceftolozane-Tazobactam in the Management of Febrile Neutropenia in Patients with Hematological Malignancies
por: Chaftari, Anne-Marie, et al.
Publicado: (2020) -
Procalcitonin Guiding Antimicrobial Therapy Duration in Febrile Cancer Patients with Documented Infection or Neutropenia
por: Haddad, Hanine El, et al.
Publicado: (2018) -
A Prospective Randomized Study Comparing Ceftolozane/Tazobactam to Standard of Care in the Management of Neutropenia and Fever in Patients With Hematological Malignancies
por: Chaftari, Anne-Marie, et al.
Publicado: (2022)